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During bronchoscopy hypoxemia is commonly found and oxygen supply can be delivered by interfaces fed with high gas ﬂows.
Recently, the high-ﬂow nasal cannula (HFNC) has been introduced for oxygen therapy in adults, but they have not been used so
far during bronchoscopy in adults. Forty-ﬁve patients were randomly assigned to 3 groups receiving oxygen: 40L/min through
a Venturi mask (V40, N = 15), nasal cannula (N40, N = 15), and 60L/min through a nasal cannula (N60, N = 15) during
bronchoscopy. Gas exchange and circulatory variables were sampled before (FiO2 = 0.21), at the end of bronchoscopy (FiO2 =
0.5), and thereafter (V40, FiO2 = 0.35). In 8 healthy volunteers oxygen was randomly delivered according to V40, N40, and N60
settings, and airway pressure was measured. At the end of bronchoscopy, N60 presented higher PaO2,P a O 2/FiO2, and SpO2 than
V40 and N40 that did not diﬀer between them. In the volunteers (N60) median airway pressure amounted to 3.6cmH2O. Under
a ﬂow rate of 40L/min both the Venturi mask and HFNC behaved similarly, but nasal cannula associated with a 60L/min ﬂow
produced the better results, thus indicating its use in mild respiratory dysfunctions.
1.Introduction
During bronchoscopy hypoxemia is commonly found [1–
3]. PaO2 usually drops approximately 20mmHg during the
procedure [1, 4], and the worst decrease occurs during
bronchoalveolar lavage (BAL) [5]. Age, gender, and baseline
peripheral oxygen saturation (SpO2) are not reliable pre-
dictive variables of hypoxemia [6]t h a tm a yp e r s i s ts e v e r a l
hours after the procedure [1, 7] and increase the incidence
of cardiac arrhythmia [8].
Toavoidbronchoscopy-inducedhypoxemia,oxygensup-
ply can be delivered by interfaces fed with low (6L/min) or
high gas ﬂows. Low-ﬂow systems supply oxygen according
to the patients’ respiratory pattern, which limits their use
[9]. Hence, clinically high-ﬂow interfaces are generally used,
and among them the Venturi mask has been the most
commonly employed device. Recently, the high-ﬂow nasal
cannula (HFNC) has been introduced for oxygen therapy in
adults[10–13],asanaturalextensionoftheiruseinneonates
and children [14–16]. The eﬀectiveness of both devices has
been compared so far in adult human beings with acute
respiratory failure in a sequential interventional study [11]
and in a randomized work in patients with mild to moderate
hypoxemic respiratory failure [12]. Both groups report a
better performance of the HFNC device using maximum
ﬂows of 30 and 35L/min, respectively. Additionally, to our
knowledge these cannulas and heated/humidiﬁed circuits
have not been used so far during bronchoscopy in adult
human beings. Finally, a CPAP-like eﬀect was reported in
patients [17] and healthy volunteers [18] using a high-ﬂow
nasal cannula. Furthermore, it seems to display a ﬂow-
dependent behaviour [18].2 Critical Care Research and Practice
Thus, we aimed at determining the eﬀects of high-ﬂow
devices on gas exchange and cardiovascular variables in
patients undergoing bronchoscopy and BAL. In all instances
oxygen was supplemented by a Venturi mask or by a high-
ﬂow nasal cannula. Furthermore, two gas ﬂow rates were
applied to the latter device in order to better understand
its biophysical/clinical behaviour. We compared not only
the diﬀerent devices/ﬂows but also the same device along
the overall bronchoscopy procedure. To verify whether a
CPAP could be developed by high-ﬂow rates, healthy awake
volunteers were studied.
2.MaterialsandMethods
2.1. Study Design. Forty-ﬁve patients (21 females and 24
males) ranging from 37 to 83 years of age and with a
body max index (BMI) ranging from 21 to 30 (Table 1)
were enrolled in the study that had been approved by our
institutional review board. Informed signed consent was
obtained from all patients. The clinical indications for bron-
choscopy were idiopathic lung consolidation (n = 19); lung
consolidation in the course of antibiotic therapy (n = 10);
lung consolidation in immuno compromised patients (n =
5); eosinophilic pneumonia (n = 3); collagenopathy (n = 2);
hemoptysis (n = 2); Churg-Strauss syndrome, asbestosis,
lymphangioleiomyomatosis, and alveolar microlithiasis (n =
1i ne a c hc a s e ) .
2.2. Methods. All patients were selected by the Pneumology
Department,CattinaraUniversityHospital,toundergoﬁbre-
optic bronchoscopy and BAL ﬂuid collection as a diagnostic
tool for pulmonary disease. They were included in the study
if peripheral arterial pulse oximetry (SpO2)w a s≥90%, age
≥18 years, did not present either respiratory or cardiac
failure, and were able to breathe spontaneously throughout
ﬁbreoptic bronchoscopy. Those subjects with body mass
index (BMI) ≥30, tracheostomy, requiring home oxygen
therapy and/or mechanical or noninvasive ventilation, nasal
and/or nasopharyngeal disease, not able to clearly express
themselves, and pregnancy were excluded from the study.
The patients were randomly assigned to three groups
(N = 15 in each one) by a physician unaware of the study:
groups V40 and N40 received oxygen (40L/min, FiO2 = 0.5)
through a Venturi mask (OS/62K, FIAB, Vicchio, Italy) and
HFNC (RT050, Fisher & Paykel, Auckland, New Zealand)
during bronchoscopy, respectively (Figures 1(a) and 1(b),
resp.). N60 patients also received oxygen through the
aforementioned HFNC during bronchoscopy, but a higher
ﬂow rate was delivered (60L/min, FiO2 = 0.5), as shown
in Figure 1(b). Oxygen/air mixture in V40 group was
controlled by an air entrainer with the Venturi eﬀect (RT008,
Fisher & Paykel, Auckland, New Zealand), whereas in N40
and N60 a continuous high-ﬂow generator with Venturi
eﬀect (9293/D, Harol, San Donato, Italy) was used. In all
instances the patients were in the supine position, and the
administered gas mixture was humidiﬁed and warmed by
a servo-controlled heated respiratory humidiﬁer (MR730,
Fisher & Paykel, Auckland, New Zealand), as depicted in
Figure 1.F i O 2 was measured on the inspiratory line by
an oxymeter (5120 Oxygen Monitor, Datex-Ohmeda, Inc,
Madison, WI, USA) (Figure 1). Baseline PaO2,P a C O 2,p H
(Rapidlab 865, Bayer, Leverkusen, Germany), SpO2,h e a r t
rate (HR), and non-invasive mean arterial pressure (MAP)
(Dinamap, General Electrics, WI, USA) were measured
duringspontaneousbreathinginroomair(t0,Table 1).PAO2
was calculated by the alveolar gas equation, assuming the
respiratory quotient equal to 0.8 and barometric pressure
as 760mmHg. Arterial/alveolar PO2 ratio (a/APO2)a n d
ratio between PaO2 and inspiratory fraction of oxygen
(PaO2/FiO2) were then arithmetically calculated. A venous
catheter was indwelled to secure a line for administration of
drugs and saline solution. After 5min of oxygen (FiO2 = 0.5)
administration, local anaesthesia (nebulised lidocaine 2%,
8–10mL) was performed through the mouth and nostrils.
A 10min resting period was allowed to guarantee fully
developed local anaesthesia. Conscious intravenous seda-
tion was achieved by means of midazolam delivered as
demanded by each patient, reaching a maximum dose of
0.1mg/kg BW. Fibreoptic bronchoscopy (18-F, Olympus
Corp, Tokyo, Japan) was immediately initiated through a
dedicated mouthpiece (Pentax Europe GmbH, Hamburg,
Germany). Bronchoalveolar lavage was done with 150mL of
warmed saline solution (NaCl 0.9%) and ﬂuid was aspirated
always by the same pneumologist, who had not later access
to the raw data. At this point gas exchange and circulatory
variables were sampled (t1). At the end of the procedure that
lasted from 8 to 34min, all patients were switched to V40
settingwithaFiO2 =0.35forarestingperiodof10min.Then
(t2), the last data sampling took place.
Before discharging the patient from the bronchoscopy
room, he/she was asked to describe the level of comfort
during the procedure according to a scale: 1 = excellent,
2 = good, 3 = mild, and 4 = poor.
Additionally, eight healthy volunteers ranging from 25
to 37 years of age and presenting 20 to 24 BMI (4 females
and 4 males) rested in supine position and underwent local
anaesthesia as aforementioned. A 35cm long 14-F catheter
(Willy R¨ usch GmbH, Kernen, Germany) with two side-
holes and another distal one were introduced through the
nostril, its distal end reaching the hypopharynx. Its correct
positioning in the pharynx was detected by gas sampling
and CO2 monitoring (CO2SMO Plus 8100, Novametrix
Medical System, Inc., Wallingford, CT, USA) as follows:
when a normal capnographic curve resulted, the catheter
was considered correctly placed; otherwise it was moved
up and down until adequately positioned. The volunteers
were attached to the dedicated mouthpiece (Pentax Europe
GmbH, Hamburg, Germany) partially obstructed by an
occluded tracheal tube (size 5, OD 6.7mm, R¨ uschlit, Willy
R¨ usch GmbH, Kernen, Germany) that simulated the ﬁbre-
optic bronchoscope. The tracheal tube distal end was always
within the mouthpiece. Oxygen (FiO2 = 0.28) was randomly
delivered according to V40, N40, and N60 settings, and
airway pressure was measured through the nasally intro-
ducedcatheterbytheCO2SMOPlus8100RespiratoryProﬁle
Monitor (Novametrix Medical System, Inc., Wallingford,
CT, USA). A 5min resting period was allowed betweenCritical Care Research and Practice 3
Table 1: Anthropometric, respiratory, and cardiovascular data under facial and diﬀerent nasal interfaces.
Variables V40 N40 N60
Baseline (t0,F i O 2 = 0.21)
Gender (M/F) 9/6 8/7 7/8
Age (years) 68.0 (62.0–78.0) 70.0 (61.0–76.0) 64.0 (63.0–70.0)
BMI (kg/m2) 26.5 (22.5–29.1) 25.0 (21.4–28.0) 25.7 (21.2–28.9)
pH 7.45 (7.44–7.48) 7.47 (7.43–7.49) 7.46 (7.42–7.47)
PaCO2 (mmHg) 37.5 (35.0–42.1) 39.1 (37.3–41.5) 39.6 (33.4–42.5)
PaO2/FiO2 322.4 (295.6–374.3) 342.8 (295.7–371.9) 350.9 (304.3–363.8)
a/A PO2 0.674 (0.587–0.764) 0.723 (0.652–0.745) 0.718 (0.659–0.765)
PaO2 (mmHg) 67.7 (62.1–78.6) 72.0 (62.1–78.1) 73.7 (63.9–76.4)
SpO2 (%) 94 (93–96) 95 (91–96) 95 (93–97)
HR (bpm) 75.0 (62.0–97.0) 78.0 (72.0–85.0) 74.0 (68.0–84.0)
MAP (mmHg) 94.0 (90.0–107.0) 102.0 (92.0–112.0) 109.0 (100.0–117.0)
End of bronchoscopy (t1,F i O 2 = 0.50)
pH 7.41 (7.38–7.44)∗ 7.41 (7.38–7.44)∗ 7.40 (7.36–7.40)∗
PaCO2 (mmHg) 42.7 (41.0–44.4)∗ 43.2 (37.9–47.6)∗ 43.6 (42.4–48.0)∗,+
PaO2/FiO2 165.0 (127.4 −199.2)∗ 140.6 (125.6–153.6)∗ 244.8 (181.6–366.8)+,++
a/A PO2 0.265 (0.207–0.326)∗ 0.224 (0.204 - 0.249)∗ 0.401 (0.295–0.604)∗,+,++
PaO2 (mmHg) 82.5 (63.7–99.6) 70.3 (62.8–76.8) 122.4 (90.8–183.4)∗,++
SpO2 (%) 94 (92–96) 92 (90–95) 98 (97–99)∗,+,++
HR (bpm) 90 (76–110)∗ 84 (80–101) 84 (70–100)∗
MAP (mmHg) 108.0 (92.0–126.0) 99.0 (94.0–105.0) 103.0 (93.0–117.0)
Duration (min) 14.0 (10.0–16.0) 15.0 (12.0–16.0) 15.0 (9.0–20.0)
10 minutes after bronchoscopy (t2,F i O 2 = 0.35)
pH 7.42 (7.40–7.45)∗ 7.41 (7.39–7.44)∗,∗∗ 7.40 (7.40–7.44)∗,∗∗
PaCO2 (mmHg) 42.2 (39.7–43.2)∗ 43.4 (41.0–45.7)∗ 40.7 (38.0–45.5)
PaO2/FiO2 248.6 (206.6–274.3)∗,∗∗ 224.3 (206.6–249.1)∗,∗∗ 278.8 (222.9–304.0)∗
a/A PO2 0.441 (0.342–0.515)∗,∗∗ 0.421 (0.352- 0.446)∗,∗∗ 0.480 (0.389- 0.536)∗
PaO2 (mmHg) 87.0 (72.3–101.8) 78.5 (72.3–87.2) 97.6 (78.0–106.4)∗,∗∗
SpO2 (%) 95 (92–98) 93 (91–95) 95 (95–98)∗∗,+
HR (bpm) 82.0 (75.0–90.0)∗∗ 80.0 (79.0–91.0)∗ 76.0 (64.0–89.0)∗∗
MAP (mmHg) 91.0 (83.0–103.0) 94.0 (85.0–98.0)∗∗ 96.0 (87.0–108.0)
Values are median (1st–3rd quartiles). V40, N40: patients that received oxygen (40L/min, FiO2 = 0.5) through a Venturi mask and nasal prong; respectively,
N60: patients that received oxygen (60L/min, FiO2 = 0.5) through a nasal high-ﬂow interface; baseline: FiO2 = 0.21; end of bronchoscopy: airﬂow according
to V40, N40, and N60, FiO2 = 0.5; 10min after bronchoscopy: 15L/min, FiO2 = 0.35; PaCO2 and PaO2: arterial partial pressures of CO2 and O2;r e s p e c t i v e l y ,
BMI: body mass index; PaO2/FiO2: ratio between PaO2 and inspiratory fraction of O2;a / AP O 2: ratio between arterial and alveolar PO2; SpO2: peripheral
oxygen saturation; HR: heart rate; MAP: mean arterial pressure, duration: length of bronchoscopy. ∗Signiﬁcantly diﬀerent from t0; ∗∗signiﬁcantly diﬀerent
from t1; +signiﬁcantly diﬀerent from V40; ++signiﬁcantly diﬀerent from N40; signiﬁcance level = 5%.
two diﬀerent oxygen delivery settings. In all instances the
experiment did not last more than 30min.
2.3. Analysis. Statistical analysis was performed using Sta-
tistica 6.1 software (StatSoft, Vigonza, Italy). Normality
was assessed by the Kolmogorov-Smirnov-Lilliefors test.
Since in all instances normal distribution was not satisﬁed,
descriptive statistics were provided using median and 1st–
3rd quartiles. Mann-Whitney and the Wilcoxon tests were
used to pairwise compare data among diﬀerent oxygen
delivery systems/ﬂows and among diverse points along the
experimental timeline, respectively. Multiple comparisons
were controlled for the false discovery rate [19, 20]. In all
instances, the initial signiﬁcance level was set at 5%, and the
adjusted P values are provided when signiﬁcant.
A 3-sample test for equality of proportions was used to
evaluate the male/female distribution. The level of comfort
was assessed by permutation tests implemented in R coin
package [21]. Signiﬁcance level was 5%.
3. Results
Patients’ anthropometric and experimental data are listed in
Table 1. The results will be presented ﬁrstly as function of
time (t0, t1, t2) and, then, among groups (N40, N60, V40).
At time t0 no diﬀerence among the 3 groups could be
disclosed (Table 1). At the end of bronchoscopy (t1), in N60
patients a/A PO2,P a O 2/FiO2,a n dS p O 2 were larger than
those in V40 and N40. In N60 PaO2 and PaCO2 were higher
than those in N40 and V40, respectively. V40 and N40 did4 Critical Care Research and Practice
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Figure 1: Diagram of the experimental setups. (a) Setup used for a ﬂow rate of 40L/min. (1) Venturi mask. (2) Pneumotachograph. (3)
Oxymeter. (4) Heater/humidiﬁer. (5) Air entrainer with the Venturi eﬀect. (6) Wall mounted oxygen supply. (b) Setup used for delivering an
airﬂow of 60L/min. (1) High-ﬂow nasal cannula. (2) Pneumotachograph. (3) Oxymeter. (4) Heater/humidiﬁer. (5) Continuous high-ﬂow
generator with the Venturi eﬀect.
not diﬀer between in all instances. No diﬀerences in pH, HR,
and MAP values were found among the groups. Ten minutes
after the end of bronchoscopy (t2), SpO2 between N60 and
V40 was the only detected diﬀerence.
In V40 groupa/A PO2 andPaO2/FiO2 presenteddiﬀerent
values in all occasions. PaCO2 was smaller, and pH was
higher in t0 than that in t1 and t2.H Rw a sh i g h e ri nt1 than
in t0 and t2. In N40 group a/A PO2,P a O 2/FiO2, and pH
presented diﬀerent values at all times. PaCO2 was smaller in
t0 than in t1 and t2.H Ra n dM A Pw e r eh i g h e ri nt2 than in
t0 and t1,r e s p e c t i v e l y .I nN 6 0g r o u pP a O 2 and pH presented
diﬀerentvaluesinallinstances,a/APO2 washigherint0 than
in t1 and t2,a n dP a O 2/FiO2 was higher in t0 than in t2.S p O 2
and HR were higher in t1 than in t0 and t2, and PaCO2 was
smaller in t0 than in t1 (Table 1).
Bronchoscopy duration was similar in all groups (15, 14,
and 15min in V40, N40, and N60, resp., P = 0.69) as well
as the amount of midazolam used (4mg in each group, P =
0.95). Bronchoalveolar lavage ﬂuid aspirated was smaller in
V40 (43mL) than in N40 (75mL) and N60 (73mL) that did
not diﬀer in between, (P = 0.0005). Gender, age and BMI
did not diﬀer among the groups (Table 1).
There was no diﬀerence among the level of comfort
among V40 (level 4 = 7, level 3 = 6, and level 2 = 2), N40
(level 4 = 9, level 3 = 5, and level 2 = 1), and N60 (level 4 = 8,
level 3 = 7), P = 0.569.
Finally, in the normal volunteers end-expiratory airway
pressure amounted to 3.6 (2.4–4.0) cmH2O (median (1st–
3rd quartiles)) using a high-ﬂow nasal cannula and under-
going a ﬂow of 60L/min. In the other two experimental set-
tings, no measurable end-expiratory pressure was detected.
4. Discussion
During bronchoscopy gas exchange is usually impaired
owing to sedation and mismatching of the ventilation-
perfusion relationship (bronchoalveolar lavage, increased
airway resistance due to the presence of the ﬁbroptic
bronchoscope, and gas aspiration through the ﬁbreoptic
bronchoscopethatmayresultinatelectasis)[22].Hypoxemia
can be treated with low- and high-ﬂow oxygen delivery
[1]. For such purpose the Venturi mask is commonly used.
Recently, the high-ﬂow nasal cannula has been introduced
for oxygen therapy in adults [10–13, 23]. To our knowledge
these cannulas have not been used so far during bron-
choscopyinadults.Thus,weaimedatdeterminingtheeﬀects
of high-ﬂow devices on gas exchange and cardiovascular
variables in patients undergoing bronchoscopy and BAL. To
verifywhetheraCPAPcouldbedevelopedbyhigh-ﬂowrates,
healthy awake volunteers were studied.
High-ﬂow rates reduce the nasopharyngeal dead space,
thus improving ventilation and oxygenation [11, 12, 24].
Mouth breathing may increase this phenomenon as a
result of the reservoir eﬀect produced by the mouth and
nasopharynx gas volume [18]. In our patients oxygenation
was further improved by a FiO2 equal to 50% during
bronchoscopy. Furthermore, humidiﬁed and warmed high
ﬂows improve lung conductance and compliance, inhibiting
bronchoconstriction and reducing the metabolic cost of O2
[24].
Our 3 groups of patients presented similar demographic
characteristics. Despite the statistically signiﬁcant results
obtained for some variables in our study, only the diﬀerences
that presented clinical relevance will be discussed. In all
instances, no diﬀerence in respiratory and cardiovascular
measurements could be found between V40 and N40.
Thus, at this ﬂow rate both devices were equally eﬀective.
However, under N60 a/A PO2,S p O 2,a n dP a O 2/FiO2 were
higher than those in V40 and N40, thus indicating a better
oxygenation under these experimental conditions at the end
of bronchoscopy. Indeed, in N60 a/A PO2 and PaO2/FiO2
did not vary signiﬁcantly between the end of bronchoscopy
and 10min after bronchoscopy, whereas the values at the
three experimental sampling occasions diﬀered among them
in V40 and N40. We calculated the PaO2/FiO2 and the a/A
ratio because they are relatively unaﬀected by FiO2 and in
particular the a/A ratio is less dependent on the patient’s
age [25, 26]. In this way, the absolute PaO2 value assumes
a secondary clinical relevance.Critical Care Research and Practice 5
Carbon dioxide kinetics returned to baseline values in
N60 while in V40 and N40 at 10 minutes after bronchoscopy
PaCO2 did not return to control levels. However, several
studies reported diﬀerent PaCO2 behaviours during HFNC,
and thus the carbon dioxide wash-out mechanism is still not
widely accepted [27] as the main physiological eﬀect under
this condition.
Possibly the development of CPAP owing to the even
higher ﬂow rate achieved with the HFNC, a smaller pos-
sibility to dilute the delivered mixture by room air, and
a more constant FiO2 would explain these ﬁndings [27,
28]. The Venturi mask could not be tested with 60L/min
because of a technical limitation of the air entrainer itself,
as stated by the manufacturer (RT008, Fisher & Paykel,
Auckland, New Zealand, REF 185041357 Rev E 2009-07).
Our results demonstrated that the association of HFNC
and 60L/min ﬂow provided the better oxygenation not only
during bronchoscopy but also during recovery. HFNC with
smaller ﬂow than ours also proved to be more eﬀective than
the face mask in hypoxemic respiratory failure [11, 12].
In our study we chose an oxygen delivery of 50% in
order to minimize hypoxemia during bronchoscopy. After
the procedure, during 10 minutes an oxygen delivery of 35%
was used to evaluate the patients’ recovery.
We ran a second set of experiments on healthy volunteers
toverifywhetheraCPAPcouldindeedbedevelopedbyhigh-
ﬂow rates. This measurement was not done in the patients
to avoid an undesirable extra burden during the procedure.
The volunteers underwent the same three settings applied to
the patients. The volunteers’ median airway pressure under
V40 and N40 settings was nil, but a value of 3.6cmH2O
was measured at end expiration under N60 conditions in
volunteers with a partially obstructed mouth. Our results
are in line with those previously reported. Indeed, a CPAP-
like eﬀect has been recently reported in postoperative cardiac
surgery patients (2.7cmH2O, 35L/min) [17] and in normal
volunteers (2.7 cmH2O open mouth, and 7.4cmH2O closed
mouth, 60L/min) [18], and it has been demonstrated that
positive nasopharyngeal pressure increases with increasing
ﬂow [18]. This CPAP could possibly contribute to the better
oxygenation in our patients.
Since the level of comfort was identical in the three
groups of patients, one can possibly assume that the three
experimental settings were similarly supported by them.
Furthermore, our patients tolerated very well the HFNC. In
this line, it has been demonstrated that patients chose to
continue with HFNC after having tried it [11].
In conclusion, under a ﬂow rate of 40L/min both the
Venturi mask and the high ﬂow nasal cannula behaved
similarly, but the outcome produced by the latter associated
with a ﬂow of 60L/min was clinically more important.
Perhaps the latter association could protect to a larger extent
patients with mild respiratory dysfunctions.
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